Showing results (771-780 of 828) with videos related to
Sort By:
Pageof 83
Archives of Pathology & Laboratory Medicine|January 14, 2020
Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline UpdateKimberly H Allison, M Elizabeth H Hammond, Mitchell Dowsett, et al.JAMA Oncology|December 11, 2025
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical TrialIrene M Kang, Jamie K Forschmiedt, Michelle M Loch, et al.Archives of Pathology & Laboratory Medicine|October 9, 2013
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateAntonio C Wolff, M Elizabeth H Hammond, David G Hicks, et al.Journal of the National Cancer Institute|December 28, 2020
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working GroupTorsten O Nielsen, Samuel C Y Leung, David L Rimm, et al.JAMA Oncology|April 12, 2019
Current Landscape of Immunotherapy in Breast Cancer: A ReviewSylvia Adams, Margaret E Gatti-Mays, Kevin Kalinsky, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I TrialCostanza Paoletti, Gaia Schiavon, Emily M Dolce, et al.The Lancet. Oncology|December 17, 2009
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialKathy S Albain, William E Barlow, Steven Shak, et al.Journal of the National Cancer Institute|December 10, 2024
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trialYara Abdou, William E Barlow, Julie R Gralow, et al.Clinical Breast Cancer|April 1, 2019
Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways StudyVictoria Larsen, William E Barlow, Jun J Yang, et al.NEJM Evidence|July 23, 2024
Clinical and Genomic Risk for Late Breast Cancer Recurrence and SurvivalJoseph A Sparano, Michael Crager, Robert J Gray, et al.Pageof 83